WHO warns against use of ivermectin to treat coronavirus infections

A day after Goa's Health Minister Vishwajit Rane recommended ivermectin to all above 18 to combat Covid in the state, the World Health Organisation on Tuesday has warned against its use

WHO warns against use of ivermectin to treat coronavirus infections
IANS New Delhi
3 min read Last Updated : May 11 2021 | 4:06 PM IST

A day after Goa's Health Minister Vishwajit Rane recommended ivermectin to all above 18 to combat Covid in the state, the World Health Organisation on Tuesday has warned against its use.

'Safety and efficacy are important when using any drug for a new indication. @WHO recommends against the use of ivermectin for #COVID19 except within clinical trials,' Soumya Swaminathan, the global health body's chief scientist, said in a tweet.

 

The Goa state government on Monday cleared a new Covid treatment protocol which recommends all residents above the age of 18 to take five tablets of the ivermectin drug, in order to prevent the steep and sometimes fatal viral fever, which accompanies a Covid-19 infection.

 

Rane, while speaking to reporters, said that the ivermectin drug would be made available at all health centres in the state and should be taken by all residents, irrespective of whether they have Covid-19 symptoms or otherwise.

 

Last week, a peer-reviewed research had claimed that global ivermectin use can end Covid-19 pandemic, as the medicine significantly reduces the risk of contracting the deadly respiratory disease when used regularly.

 

The peer review, which included three US government senior scientists and was published in the American Journal of Therapeutics, touted the common anti-parasitic ivermectin as a miracle cure for Covid-19 by doctors and campaigners the world over.

 

In her tweet, Swaminathan also attached a warning issued by the German health care and life sciences giant Merck.

 

'Scientists continue to carefully examine the findings of all available and emerging studies of ivermectin for the treatment of Covid-19,' read the statement from Merck.

 

'...to-date, our analysis has identified: No scientific basis for a potential therapeutic effect against Covid-19 from pre-clinical studies; No meaningful evidence for clinical activity or clinical efficacy in patients with Covid-19 disease, and; A concerning lack of safety data in the majority of studies,' the statement added.

 

The WHO had, in March, issued a similar warning against the use of ivermectin in treating Covid patients.

 

The global health agency said that there was a 'very low certainty of evidence' on ivermectin's effects on mortality, hospital admission and getting rid of the virus from the body.

 

Rane also stated that expert panels from the UK, Italy, Spain and Japan, found a large, statistically significant reduction in mortality, time to recovery and viral clearance in Covid-19 patients treated with ivermectin.

 

The US Food and Drug Administration (FDA) had also, in April last year, recommended against the use of ivermectin in treating Covid patients. Besides, the Union ministry of health and family welfare had also reportedly opted out from including Ivermectin in its official Clinical Management Protocol for Covid-19 last year.

 

--IANS

rvt/rs/ash

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusWHOWorld Health Organization

First Published: May 11 2021 | 4:04 PM IST

Next Story